Dożylna infuzja lidokainy w operacji fuzji lędźwiowej
Wpływ dożylnej infuzji lidokainy śródoperacyjnej na zużycie opioidów pooperacyjnych i powrót do zdrowia po operacji fuzji lędźwiowej: Randomizowane badanie kontrolowane
Elective lumbar fusion surgery is associated with moderate to severe postoperative pain and often requires substantial perioperative opioid administration. Excessive opioid use may lead to adverse effects such as nausea, vomiting, sedation, respiratory depression, and delayed mobilization. Intravenous lidocaine infusion has been proposed as part of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties.
This randomized, placebo-controlled clinical trial aims to evaluate the effect of intraoperative intravenous lidocaine infusion on postoperative opioid consumption and early recovery outcomes in patients undergoing elective lumbar fusion surgery. Patients will be randomly assigned to receive either intravenous lidocaine infusion or placebo during surgery.
The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores, time to first rescue analgesic, quality of recovery, postoperative nausea and vomiting, time to mobilization, and length of hospital stay. In addition, inflammatory and oxidative stress biomarkers including interleukin-6 (IL-6) and markers of thiol-disulfide homeostasis will be measured preoperatively and postoperatively.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Lumbar fusion surgery is frequently associated with significant postoperative pain and often requires high doses of opioid analgesics during the perioperative period. Opioid administration may lead to several adverse effects including postoperative nausea and vomiting, sedation, respiratory depression, and delayed recovery. Therefore, multimodal analgesia strategies are increasingly used to improve postoperative pain control and reduce opioid requirements.
Intravenous lidocaine infusion has gained attention as an adjunct component of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties. Previous clinical studies have suggested that perioperative systemic lidocaine may reduce postoperative pain intensity, decrease opioid consumption, and improve recovery after surgery. However, evidence regarding its effectiveness in patients undergoing lumbar fusion surgery remains limited.
This prospective, randomized, placebo-controlled study will include adult patients aged 18 years or older with American Society of Anesthesiologists (ASA) physical status I-III who are scheduled for elective lumbar fusion surgery. Participants will be randomly allocated into two groups. Patients in the lidocaine group will receive an intravenous lidocaine bolus followed by continuous lidocaine infusion during surgery, whereas patients in the control group will receive an equivalent volume of normal saline infusion. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.
All patients will receive standardized general anesthesia and postoperative multimodal analgesia. Postoperative pain will be assessed using the Numerical Rating Scale (NRS). Rescue analgesia will be administered when clinically indicated.
The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores at predefined time points, time to first rescue analgesic requirement, postoperative nausea and vomiting incidence, quality of recovery measured by QoR-15, post-anesthesia care unit length of stay, time to mobilization, and hospital length of stay.
In addition, inflammatory and oxidative stress responses associated with surgery and lidocaine administration will be evaluated. Blood samples will be collected preoperatively and at 6 and 24 hours postoperatively to measure interleukin-6 (IL-6) levels and markers of thiol-disulfide homeostasis.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Ankara Bilkent City Hospital
- Numer telefonu: +90 312 552 6000
- E-mail: ankarasehir@saglik.gov.tr
Lokalizacje studiów
-
-
-
Ankara, Turcja (Türkiye)
- Rekrutacyjny
- Ankara Bilkent City Hospital
-
Kontakt:
- Gokhan Erdem, MD, PhD
- Numer telefonu: 05326258766
- E-mail: drgokhanerdem@gmail.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age ≥18 years
- Scheduled for elective lumbar fusion surgery under general anesthesia
- American Society of Anesthesiologists (ASA) physical status I-III
- Ability to provide written informed consent
Exclusion Criteria:
- Refusal to participate in the study
- ASA physical status ≥IV
- Body mass index >35 kg/m²
- Known allergy or hypersensitivity to lidocaine or study medications
- Severe cardiac, hepatic, or renal disease
- Pregnancy
- Neurological disorders affecting pain assessment
- Chronic opioid use
- Use of opioids or antiemetic drugs before surgery
- Inability to cooperate with postoperative assessments
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Lidocaine Infusion
Patients in this group will receive continuous intravenous lidocaine infusion at a rate of 2 mg/kg/h throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia. |
Continuous intravenous lidocaine infusion will be administered during lumbar fusion surgery at a rate of 2 mg/kg/h following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery. |
|
Komparator placebo: Placebo (Normal Saline)
Patients in this group will receive an intravenous infusion of normal saline at an equivalent rate throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia. |
An intravenous infusion of normal saline (0.9% sodium chloride) will be administered at an equivalent rate during surgery following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Cumulative postoperative opioid consumption within the first 24 hours after surgery
Ramy czasowe: 0 to 24 hours after surgery
|
Cumulative opioid consumption during the first 24 postoperative hours will be evaluated. Rescue analgesia will be administered as intravenous tramadol (100 mg) when the Numerical Rating Scale (NRS) pain score is ≥4. The cumulative tramadol dose administered during this period will be recorded in milligrams (mg). |
0 to 24 hours after surgery
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Intraoperative remifentanil consumption
Ramy czasowe: From induction of anesthesia to the end of surgery
|
Cumulative remifentanil consumption during surgery will be recorded in micrograms (µg). |
From induction of anesthesia to the end of surgery
|
|
Postoperative pain intensity
Ramy czasowe: At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery
|
Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain). |
At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery
|
|
Time to first rescue analgesic requirement
Ramy czasowe: Within the first 24 hours after surgery
|
Time from the end of surgery to the first administration of rescue intravenous tramadol will be recorded. |
Within the first 24 hours after surgery
|
|
Quality of recovery
Ramy czasowe: Preoperative baseline and 24 hours after surgery
|
Quality of recovery will be evaluated using the Quality of Recovery-15 (QoR-15) questionnaire, a validated patient-reported outcome measure assessing postoperative recovery. The total score ranges from 0 to 150, with higher scores indicating better postoperative recovery. |
Preoperative baseline and 24 hours after surgery
|
|
Postoperative nausea and vomiting incidence
Ramy czasowe: 0-24 hours after surgery
|
The incidence of postoperative nausea and/or vomiting and the requirement for rescue antiemetic treatment will be recorded. |
0-24 hours after surgery
|
|
Post-anesthesia care unit length of stay
Ramy czasowe: Immediate postoperative period (up to 24 hours after surgery)
|
Duration of stay in the post-anesthesia care unit will be recorded in minutes. |
Immediate postoperative period (up to 24 hours after surgery)
|
|
Time to mobilization
Ramy czasowe: Up to 24 hours after surgery
|
Time from the end of surgery to the first mobilization will be recorded. |
Up to 24 hours after surgery
|
|
Serum interleukin-6 (IL-6) levels
Ramy czasowe: Preoperatively and at 6 and 24 hours after surgery
|
Serum interleukin-6 (IL-6) levels will be measured to evaluate the inflammatory response. |
Preoperatively and at 6 and 24 hours after surgery
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Thiol-disulfide homeostasis parameters
Ramy czasowe: Preoperatively and at 6 and 24 hours after surgery
|
Native thiol, total thiol, and disulfide levels will be measured to evaluate oxidative stress and thiol-disulfide homeostasis. |
Preoperatively and at 6 and 24 hours after surgery
|
|
Length of hospital stay
Ramy czasowe: Through hospital discharge, an average of 5 days
|
Total duration of hospitalization will be recorded in days. |
Through hospital discharge, an average of 5 days
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Gokhan Erdem, MD, PhD, Department of Anesthesiology and Reanimation, Ankara Bilkent City Hospital, Ankara, Turkey
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Ból
- Objawy neurologiczne
- Powikłania pooperacyjne
- Procesy patologiczne
- Stany patologiczne, oznaki i objawy
- Objawy i symptomy
- Ból, pooperacyjny
- Organiczne chemikalia
- Przygotowania farmaceutyczne
- Anilidy
- Amides
- Związki aniliny
- Aminy
- Acetanilidy
- Rozwiązania krystaloidalne
- Rozwiązania izotoniczne
- Rozwiązania
- Lidokaina
- Roztwór soli fizjologicznej
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- LidocaineInfusion
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
No plan to share individual participant data.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .